-
Eli Lilly reaches deal to carry AI-developed medication to international market
A drone view shows the Eli Lilly logo on the company’s office in San Diego, California, November 21, 2025. Mike Blake | Reuters BEIJING – US pharmaceutical giant Eli Lilly has struck a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market. According to the…
-
Pfizer’s Lyme illness vaccine fails trial, firm applies for FDA approval
Thomas Fuller | Photo only | Getty Images Pfizer On Monday, the company said it would seek regulatory approval for a Lyme disease vaccine candidate, even though the shot failed in a late-stage trial. Pfizer said the vaccine missed the study’s statistical target because not enough people in the study had Lyme disease to rely…
-
Eating places add protein, fiber for weight reduction drug customers
A mini burger, mini fries and mini beer, Clinton Hall’s “Teeny Weeny Mini Meal”, is pictured next to a regular-sized combo on Dec. 8, 2025 in New York City. Approximately one in eight American adults are currently taking drugs from the class of GLP-1 agonists that are now popular for weight loss, according to a…
-
Eli Lilly shares slide after bearish analyst name – this is our take
Shares of Eli Lilly fell 6% on Tuesday and are on track for their worst day since February after a downgrade by HSBC. The gist of HSBC’s claim: Wall Street is overly optimistic about the size of the GLP-1 obesity market. The company’s analysts expect it to be between $80 billion and $120 billion in…
-
The Vertex kidney drug povetacicept is profitable within the examine for IgAN
A sign hangs in front of the world headquarters of Vertex Pharmaceuticals in Boston. Brian Snyder | Reuters Vertex Pharmaceuticals said its experimental drug for a rare kidney disease successfully passed a Phase 3 trial, a key step in the company’s journey to diversify beyond its main cystic fibrosis drugs. The Boston-based drugmaker said Monday…
-
Within the booming enterprise of wellness golf equipment and third areas
A few years ago, Grace Guo began to long for places in New York City where hanging out with friends didn’t necessarily have to involve alcohol. Guo was newly sober and surrounded by friends who also didn’t want to drink. She said she wanted alternatives to the typical social scene. After some research, she landed…
-
We have been lively in buying and selling in the course of the aftermath of the Iran Struggle. Jim Cramer explains our method
Jim Cramer explained Tuesday morning why the Investing Club is trying to strike a delicate balance with its actions during the Iran War’s impact on the stock market. “Those who flee in moments like these can never get back in,” Jim stressed during the morning session, as Wall Street sold off sharply on Monday following…
-
First GLP-1 anti-obesity capsule from Novo Nordisk launches within the US
The logo of pharmaceutical company Novo Nordisk is seen outside its offices in Bagsvaerd on the outskirts of Copenhagen on November 24, 2025. Tom Little | Reuters Novo Nordisk will begin rolling out the first-ever GLP-1 weight loss pill in the United States on Monday, the company announced, marking a new chapter in obesity treatment…
-
An necessary advance for Novo Nordisk’s GLP-1 capsule
Novo Nordisk flags fly in front of their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. Tom Little | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health news straight to your inbox. Subscribe here to receive future editions. A closely watched…
-
Anthropic’s Claude Life Sciences offers researchers an AI enhance
Anthropic CEO Dario Amodei speaks on CNBC’s Squawk Box before the World Economic Forum in Davos, Switzerland, on January 21, 2025. Gerry Miller | CNBC Anthropic on Monday announced Claude for Life Sciences, a new offering for researchers to use the company’s artificial intelligence to advance scientific discoveries. Claude for Life Sciences is based on…
